U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Tepotinib

Last Revision: September 20, 2021.

Estimated reading time: 1 minute

CASRN: 1100598-32-0

image 172650751 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of tepotinib during breastfeeding. Because tepotinib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of 32 hours, the manufacturer recommends that breastfeeding be discontinued during tepotinib therapy and for 1 week after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Tepotinib

CAS Registry Number

1100598-32-0

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Tyrosine Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK574076PMID: 34554673

Views

Related information

Similar articles in PubMed

  • Review Dacomitinib.[Drugs and Lactation Database (...]
    Review Dacomitinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Infigratinib.[Drugs and Lactation Database (...]
    Review Infigratinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Vandetanib.[Drugs and Lactation Database (...]
    Review Vandetanib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Osimertinib.[Drugs and Lactation Database (...]
    Review Osimertinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Gilteritinib.[Drugs and Lactation Database (...]
    Review Gilteritinib.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...